Patients must not have any known allergy or reaction to any component of the durvalumab (MEDI) and/or tremelimumab formulation Known hypersensitivity to any component of the formulation or substituted benzimidazoles Patients who have exhibited allergic reactions to a similar structural compound or to a formulation component of CX-. Known hypersensitivity or allergy to murine products or any component of the obinutuzumab, rituximab, idasanutlin, or venetoclax formulation History of hypersensitivity to any of the additives in the alectinib drug formulation History of hypersensitivity reactions to study drug or any component of the study drug formulation Known allergy or reaction to any component of either study drug formulation Known allergy or hypersensitivity to any component of the atezolizumab formulation Known hypersensitivity to immunoglobulins or to any other component of the IP formulation Known allergy or reaction to any component of either study drug formulation History of hypersensitivity and anaphylactoid reactions to pneumococcal vaccine or any component of the formulation, including diphtheria toxoid Known allergy or reaction to any component of either study drug formulation Known hypersensitivity to immunoglobulins or to any other component of the IP formulation Has known allergy or reaction to any component of either study drug or formulation components Known hypersensitivity or allergy to any component of the avelumab formulation History of hypersensitivity and anaphylactoid reactions to pneumococcal vaccine or any component of the formulation, including diphtheria toxoid History of hypersensitivity to any component of the formulation Has known hypersensitivity to pembrolizumab (MK-) or its formulation Known allergy or reaction to any component of the MEDI formulation or its excipients History of hypersensitivity to vandetanib, lactose, murine products, or any component of the formulation History of hypersensitivity to any component of the formulation History of hypersensitivity to bevacizumab, murine products, or any component of the formulation History of hypersensitivity to temsirolimus or its metabolites (including sirolimus), polysorbate , or to any component of the formulation History of hypersensitivity to cetuximab, murine products, or any component of the formulation History of hypersensitivity to any component of the formulation Patients who have exhibited allergic reactions to a similar structural compound or to a formulation component. DOSE ESCALATION COHORT: Known allergy or reaction to any component of either study drug formulation; any history of serotonin syndrome (SS) after receiving or more serotonergic drugs DOSE EXPANSION COHORT: Known allergy or reaction to any component of either study drug formulation; any history of serotonin syndrome (SS) after receiving or more serotonergic drugs Hypersensitivity to pembrolizumab or any of its excipients, or a known history of hypersensitivity to IL- or any component of the formulation Hypersensitive or intolerant to any component of the study drug(s) formulation Previous monoclonal antibody (mAb) or other treatment specifically directed against CD; history of serious allergy or reaction to any component of the MEDI- formulation that would prevent administration Patients with a history of hypersensitivity to sirolimus or any component of the formulation. Patients must not have any known allergy or reaction to any component of the MEDI formulation Known allergy or hypersensitivity to any component of the atezolizumab formulation Known allergy or hypersensitivity to any component of the bevacizumab formulation Known allergy or past administration reaction including infusion related reaction (IRRs), anaphylactic, or anaphylactoid reactions to any component of the CDX- formulation. History of hypersensitivity to any of the additives in the alectinib and crizotinib drug formulation History of hypersensitivity to any component of the formulation. Known hypersensitivity to capecitabine, fluorouracil, or any component of the formulation Known hypersensitivity to ibrutinib or any component of the ibrutinib formulation Known immediate or delayed hypersensitivity reaction to carboplatin, paclitaxel, polysorbate , or any other component of the formulation Known hypersensitivity to any component of the formulation History of hypersensitivity to any component of the formulation History of hypersensitivity to bevacizumab or murine products, temsirolimus or its metabolites, or any component of the formulation CARBOPLATIN ARM: hypersensitivity to carboplatin or any component of the formulation History of hypersensitivity to bevacizumab, murine products, or any component of the formulation History of allergy or reaction to any component of the MEDI- formulation Severe hypersensitivity reaction to treatment with another monoclonal antibody, known or suspected hypersensitivity to study drugs or any component of their formulation. Subject has known history of serious hypersensitivity reaction to ASP, or any component of the formulation used. History of hypersensitivity and anaphylactoid reactions to pneumococcal vaccine or any component of the formulation, including diphtheria toxoid Known hypersensitivity to any component of atezolizumab formulation or other study medication Subject has a known history of serious hypersensitivity to ASP, or any component of the formulation used. Known allergy or hypersensitivity to any component of the formulation of CA- used in this study Subject has known history of serious hypersensitivity reaction to ASP, or any component of the formulation used. Patients with known hypersensitivity to NT-I or any component used in the vehicle/formulation are ineligible History of hypersensitivity or allergic reaction to NRT, or any component of its formulation Has received any formulation of POS within prior days Known hypersensitivity to gemcitabine or any component of the formulation.